12

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Λ.		lica	4	٠.
м	()()	116 27	1611	S.

Yu Ren et al.

CON O 6 ZOES 26

Serial No. 10/607,031

Filed: June 26, 2003

For: ACTIVE SALT FORMS WITH TYROSINE KINASE

ACTIVITY

Art Unit: _	
Examiner:	

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- 4. Pursuant to the waiver by the Office of the requirement under 37 CFR 1.98 (a)(2)(i) dated July 11, 2003, if the filing date of this application is after June 30, 2003, copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

Date 11/3/03

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited
by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120
are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

	RELATED APPLICATION			
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE		

	·		
If th	is is inconvenient, additional copies will be submitted upon reques	it.	
6	6. In accordance with 37 C.F.R. 1.97, (check one)		
	the attached information is filed within three months of the filing da	te of the captioned case.	
\checkmark	the attached information is filed more than three months after the office Action on the merits.	filing date but prior to the m	ailing of a first
	the attached information is being filed more than three months after Office Action on the merits, but before the mailing date of a Final Action authorization is therefore given to charge Deposit Account No. 13-1.17(p).	Action or Notice of Allowand	ce. The enclosed
	the undersigned certifies that each item of information contained in cited in any communication from a foreign patent office in a countermonths prior to the filing of this Statement.		
	the undersigned certifies that no item of information contained in to a communication from a foreign patent office in a counterpart foreign person signing the certification after making reasonable inquiry, w C.F.R. 1.56(c) more than three months prior to the filing of this Sta	gn application, and, to the las known to any individual	knowledge of the
		Respectfully submitted, By: Dianne Brown Attorney For Appl Reg. No. 42,068 MERCK & CO., INC. Patent Dept., RY60-30 P.O. Box 2000 Rahway, N.J. 07065-0907 (732)594-1249 Date: November 3, 2003	

	Substitute for form 1449A/PTO				COMPLETE IF KNOWN	
	INFORMATION	INFORMATION DISCLOSURE		Application Number	10/607,031	
019	A STATEMENT B	VADDI	ICANIT	Filing Date	June 26, 2003	
	1.5 SATEMENT B	I APPL	ICANI	First Named Inventor	Yu Ren et al.	
ron	o s was o			Group Art Unit		
E LON	(whe as many shee	ets as neces	ssary)	Examiner Name		
CAT &	PAD RELIANT	of	7	Attorney Docket Number	21148	

			U.S. PA	ATENT DOCUMENTS	
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		4,876,252		Torley, et al.	10/24/1989
		5,863,924		Berger, et al.	01/26/1999
		5,463,071		Himmelsbach, et al.	10/31/1995
		5,516,775		Zimmermann, et al.	05/14/1996
		5,958,934		Berger, et al.	09/28/1999
		4,788,195		Torley, et al.	11/29/1988
		5,952,331		Berger, et al.	09/14/1999
		5,521,184		Zimmermann	05/28/1996
		5,530,000		Sanfilippo, et al.	06/25/1996
		4,649,146		Takaya, et al.	03/10/1987
		6,586,423		Bilodeau, et al.	07/01/2003
		6,586,424		Bilodeau, et al.	07/01/2003

			FOREI	GN PATENT	T DOCUMENTS	
			Foreign Patent Documen	t		Date of Publication of
Examiner Initials*	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY
1		EPO	1040831 A2		Pfizer Products Inc.	10/04/2000
		PCT	WO 95/33750		Pfizer Inc.	12/14/1995
		PCT	WO 00/62778		Bristol-Myers Squibb Co.	10/26/2000
-		PCT	WO 00/39101		AstraZeneca	07/06/2000
100		PCT	WO 95/09847		Ciba-Geigy AG	04/13/1995
		PCT	WO 00/12497 ~		Scios Inc.	03/09/2000
		PCT	WO 95/35275 -		British Biotech Pharma Ltd.	12/28/1995
		PCT	WO 00/09495		Novartis AG	02/24/2000
4 7		PCT	WO 97/44326		Hoffmann-La Roche AG	11/27/1997
		PCT	WO 97/19065		Celltech Therapeutics Ltd.	05/29/1997

Examiner Signature Date Considered

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

•	Substitute for form 1449A/PTO	AND DESCRIPTION OF THE PROPERTY OF THE PROPERT		Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE COMPLETE IF KNOWN	CE
	INFORMATION D	ISCLOSURE	Application Number	10/607,031	
	O I STATEMENT BY	A DDI ICANIT	Filing Date	June 26, 2003	
/	O . 2 SH TEMENI DI	APPLICANI	First Named Inventor	Yu Ren et al.	
	TON O E SEES S	,	Group Art Unit		
(F)	(usods many sheets o	is necessary)	Examiner Name		
-	2	of 7	Attorney Docket Number	21148	

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Documer		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
		###				
-		in pure in				
				- Control of the Cont		
					•	

			FOREIG	N PATENT	T DOCUMENTS	
			Foreign Patent Document			Date of Publication of
Examiner Initials*	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY
		PCT	WO 95/35276		British Biotech Pharma. Ltd.	12/28/1995
		PCT	WO 95/09852 -		Ciba-Geigy AG	04/13/1995
		PCT	WO 99/65884		Bristol-Myers Squibb Co.	12/23/1999
'په		PCT	WO 94/01423		Nippon Soda Co., Ltd.	01/20/1994
1		PCT	WO 99/64418		Novartis AG	12/16/1999
		EPO	0 564 409 A1		Ciba-Geigy AG	10/06/1993
		JP	7149745 A		Torii Yakuhin	06/13/1995
		JP	6475475 A		Hisamitsu Pharm.	03/22/1989
4.0		DE	19824175 A1		Novartis AG	05/29/1998
/		EPO	0 384 250		Bayer AG	08/29/1990

		=
Examiner Signature	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form * IDS Form* (IDS Folder), Merck & Co., Inc., 09/05/2003

		THE RESERVE AND THE PROPERTY OF THE PARTY OF			AND IT OF THE PERSON OF THE PE	Patent and Trademark Office; U.S DEPARTMENT OF CO	MMERCE
•	Substitute t	or form 1449A/PTO			C	OMPLETE IF KNOWN	
	INFO	tor torm 1449A/PTO DRMATION DISCLOSUR FEMENT BY APPLICAN The as many sheets as necessary) The state of the	LOSURE	Application Number	10/607,031		
	S STAT	ם יוינא בוויא איבוי	V ADDI	ICANT	Filing Date	June 26, 2003	
10		ENIENI D	I AFFL	ICANI	First Named Inventor	Yu Ren et al.	
עם: _{יו}	0 6 2003 8	ı	_4		Group Art Unit		
FERRYS		e as many sne	ets as nece	essary)	Examiner Name		
CAT &	PANEAL PRO	3	of	7	Attorney Docket Number	21148	
				-			

			U.S. PATE	NT DOCUMENTS	
Examiner Initials*	Cite No.	U.S. Patent Docur	Mind Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		•			
		·			

	FOREIGN PATENT DOCUMENTS					
Examiner Cite Initials* No.		Office	Foreign Patent Document Number	t Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
1		DE	19548415		Bayer AG	06/22/1997
		PCT	WO 01/56567		Novo Nordisk A/S	08/09/2001
		PCT	WO 01/70738		Merck Frosst Canada & Co.	09/27/2001
		PCT	WO 01/17995		Merck & Co., Inc.	03/15/2001
		PCT	WO 99/65884		Bristol-Myers SquibbCo.	12/23/1999
		PCT	WO 99/21845		Agouron Pharmaceuticals, Inc.	05/06/1999
		PCT	WO 98/32753		Merck & Co., Inc.	07/30/1998

Examiner Signature	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		C. S. Charles and C. C. Control of the Control of t			and the state of t	Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE	
•	Sub	estitute for form 1449B/PTO	(ANEXC.)		C	COMPLETE IF KNOWN	1
		NFORMATION	DIS	CLOSURE	Application Number	10/607,031	
	23		7 A TO	DI ICANT	Filing Date	June 26, 2003	
0	4 . 8	A ♥ STATEMENT BY APPLICANT	PLICANI	First Named Inventor	Yu Ren et al.		
W.	0 6 200			,	Group Art Unit		
ran		(ggfe as many sheet.	s as r	ecessary)	Examiner Name		
178	DAID PAR	4	of	7	Attorney Docket Number	21148	
			_				

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.				
_		J. Rak et al. Cancer Research, 55:4575-4580, 1995				
/		G. Gasparini and A.L. Harris, J. Clin. Oncol., 1995, 13:765-782				
		M. Toi et al., Japan. J. Cancer Res., 1994, 85:1045-1049				
(A.J. Dickinson et al., Br. J. Urol., 1994, 74:762-766				
		L.M. Ellis et al., Surgery, 1996, 120(5):871-878				
/		J.K. Williams et al., Am. J. Surg., 1994, 168:373-380				
1		A. Amirkhosravi et al., Platelets, 10:285-292 (1999)				
		S.P. Gunningham, et al., Can. Research, 61: 3206-3211 (2001)				
,		A. Giatromanolaki et al., J. Pathol. 2001; 194:101-108				
1		Michael Detmar, J. Dermatological Sci., 24 Suppl. 1, S78-S84 (2000).				
/		Hasegawa et al., Skeletal Radiol., Vol. 28, pp.41-45, 1999				
4.		Brockelsby et al., Laboratory Investigation 79:1101-1111 (September 1999)				
i		Paul et al., Nature Med 7:222-227 (2001).				
!		Matsuyama et al., J. Neurol. Sci. 186:75-79 (2001)				
		van der Flier et al., J. Infectious Diseases, 183:149-153 (2001)				

The second secon	and the second s	and the same of th	
Examiner Signature		Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form *IDS Form* (IDS Folder), Merck & Co., Inc., 09/05/2003

•	Substitute for form 1449B/PTO		Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE COMPLETE IF KNOWN	-
	INFORMATION DISCLOSURE	Application Number	10/607,031	_
	A STATE OF A DOLLO AND	Filing Date	June 26, 2003	
/	6 STATEMENT BY APPLICANT	First Named Inventor	Yu Ren et al.	
	TH O 6 TO S	Group Art Unit		
(P)		Examiner Name		
•	5 of 7	Attorney Docket Number	21148	
	A CONTRACT OF STREET OF ST		<u> </u>	

NON PATENT LITERATURE DOCUMENTS					
Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.				
	Stephen K. Smith, Trends in Endocrinology & Metabolism, Vol. 12, No. 4, pp. 147-151, May/June 2001				
	Levis et al., Blood, Vol. 98, No. 3, pp.885-887 (2001)				
	Rajesh K. Jain, Nature Medicine, Vol. 7. No. 9, pp. 987-989 (September 2001)				
.,	Giulio Jori, Lasers Med. Sci., 1990; 5: 115-120				
	Chuannong Zhou, J. Photochem. and Photobiol. 1989; 3: 299-318				
	Hendrich et al., Knee Surg Sports Traumatol Arthroscopy 5: 58-63 (1997).				
	Hall et al., Am J Hum Genet 61:785-789, 1997				
	Li et al., Gene Therapy, 1998; 5:1105-1113				
	Fathallah-Shaykh et al., J Immunol 2000; 164:217-222				
	Dougherty et al., J. Natl. Cancer Inst., 1998, 90(12): 889-905				
	Van Bruggen et al., J. Clin. Invest,. 104:1613-1620 (1999)				
-	Gerber et al., Nature Medicine, Vol. 5, No. 6, pp.623-628, 1999				
	David A. Greenberg, Drug News Perspect 11(5):265-270 (1998)				
	Nakagawa et al., FEBS Let. 473:161-164 (2000)				
	M. Shibuya et al., Oncogene, Vol. 5, pp. 519-524 (1990)				

	and the state of t	A CONTRACT OF THE CONTRACT OF	22000000000000000000000000000000000000
Examiner		Date	
Signature		Considered	
			The second secon

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

•	Substitute for form 1449B/PTO	A resident artifer of	and and the Park Mark and the Control of the Contro		COMPLETE IF KNOWN
	INFORMATION	DIS	CLOSURE	Application Number	10/607,031
,	O'STATIEMENT BY	7 A 10	DI ICANIT	Filing Date	June 26, 2003
/	Ska itwieni bi	AP	PLICANI	First Named Inventor	Yu Ren et al.
	TH 0 6 200 2		,	Group Art Unit	
	(users many sheets	s as n	ecessary)	Examiner Name	
•	SAME 6	of	7	Attorney Docket Number	21148
		_		· •	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.				
		Stem Cells, Vol. 12, pp. 1-6 (1994), by T. R. Burke, Jr.				
		Molecular Cell, Vol. 4, pp. 915-924 (1999), by B. Eliceiri, et al.				
		Oncogene, Vol. 6, pp. 1677-1683 (1991), by B. Terman, et al.				
		Nature Biotech., Vol. 17, pp. 963-968 (1999), by V. Brower				
		Nature, Vol. 407, pp. 242-248 (2000), by G. Yancopoulos, et al.				
		Nature, Vol. 407, pp. 249-257 (2000), by P. Carmeliet, et al.				
		Endocrinology, Abstract, Vol. 141, No. 5, pp. 1667-1674 (2000), by M. Deckers, et al.				
		Chem. Abst., Vol. 109, No. 8, pg. 634 (1988), N. A. Shvink				
		Chem. Abstr., Vol. 111, No. 15, pg. 761(1989), by M. Tsuji				
		Chem. Abstr., Vol. 111, No. 21, pg. 765(1989), by M. Santus				
		Chem. Abstr., Vol. 126, No. 21, pg. 666 (1997), by C. S. Ra				
		Chem. Abstr., Vol. 101, No. 11, pg. 33 (1984), by H. Nagatomi				
		Abstract, Indian J. Chem., Sect. G (1986), 25B(4), 452-5, S.E. Kulkarni, et al.				
- ()		Abstract, Eur. Pat. Appl., 35 pp., T. Takaya, et al.				
		Abstract, Acta Pol. Pharm. (1980), 37(3), 293-300, M. Santus				
_	l					

	The second secon	Marie Complete Company of the Compan
Examiner Signature	Date Considered	
Digitature	Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form * IDS Form* (IDS Folder), Merck & Co., Inc., 09/05/2003

tute for form 1449B/PTO			COMPLETE IF KNOWN			
		CLOSURE	Application Number	10/607,031		
A OUTON ATTONION TO) 3 7 A 191	DI ICANITO	Filing Date	June 26, 2003		
.11) I AP	LICANI	First Named Inventor	Yu Ren et al.		
020		,	Group Art Unit			
use as many she	ets as ne	cessary)	Examiner Name			
7	of	7	Attorney Docket Number	21148		
֓֡֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֓֓֓֓֓֓֓֓֓֜֜֜֜֜֜֓֓֓֓	FORMATION ATEMENT I	ATEMENT BY APP	TEMENT BY APPLICANT (use as many sheets as necessary)	Application Number FORMATION DISCLOSURE Application Number Filing Date First Named Inventor Group Art Unit Examiner Name	FORMATION DISCLOSURE Application Number 10/607,031 Filing Date June 26, 2003 First Named Inventor Yu Ren et al. Group Art Unit Examiner Name	

NON PATENT LITERATURE DOCUMENTS					
aminer Cite Include name of the author, title, date, page(s), volume-issue number(s) and place of publication No.					
	Abstract, Pharmacol. Res. Commun., (1982), 14(4), 359-68, M. Tandon, et al.				
	Abstract, Pharmazie (1975), 30(3), 141-7, G. Wagner, et al.				
	Annual Reports in Med. Chem., Vol. 27, pp. 139-148 (1992), Mitchell, et al.				
	Abstract, Hematol Oncol. Clin. North Am., 2002, Oct; 16(5) 1173-87, Rosen.				
	Abstract, Pharmacol. Ther. 1998, Feb. 77(2): 81-114, Lawrence et al.				
	Ann. NY Acad. Sci. 979: 80-93 (2002), Luttun et al.				
	Cancer Research, 60, 970-975, Feb. 15, 2000, Wedge et al.				
	Exp. Opin. Ther. Patents, Vol. 7(6), 571-588, 1997, Traxler.				
	Cecil Textbook of Medicine, 20th Edition, vol. 1, 1004-10, 1996, Simone.				
	·				
	Cite No.				

	The state of the s		and the second s	
Examiner Signature		Date Considered		
Signature		Considered	<u></u>	